Graft-versus-host disease (GvHD) is one of the major limitations to successful haematopoietic stem cell transplantation and occurs in 20-90% of patients following allogeneic stem cell transplant. 1 Corticosteroids are the backbone of most treatment regimens for acute GvHD, but fewer than 50% of patients show a durable response to corticosteroids. 2 Steroid-resistant acute GvHD is associated with high morbidity and mortality and is extremely difficult to manage. 3 Various pharmacological agents like antithymocyte globulin 4 and mycophenolate mofetil 5 have been used with variable responses. Recently, a number of monoclonal antibodies (anti-IL-1, anti-TNF, anti-IL-2 and anti-CD3 antibody) have been tried in steroid refractory acute GvHD with mixed results. Campath-1H (Alemtuzumab) is a humanised monoclonal antibody to CD52, an antigen expressed by T and B lymphocytes, eosinophils, monocytes and some antigenpresenting dendritic cells (DCs). 7 It has been used in conditioning regimens for allogeneic transplantation to remove donor T cells so as to prevent GvHD. 8 The induction of acute GvHD requires host antigens to be presented to donor T cells by antigen-presenting cells (APCs), such as DCs. As it is now reported that CD52 antigen is also present on monocyte-derived peripheral blood DCs, 7 it is now reasoned that Campath-1H might have a direct effect on DCs, in addition to donor T cells, both for the prevention and treatment of acute GvHD. We describe two patients who developed acute liver GvHD following allogeneic stem cell transplantation and were successfully treated with Campath-1H.
Case 1
A 36-year-old male with acute myeloid leukaemia had an allogeneic stem cell transplantation from his HLAidentical sister. The stem cell dose was 5.62 Â 10 6 CD34 cells/kg. He was conditioned with cyclophosphamide 120 mg/kg and 1440 cGy total body irradiation (TBI) in eight fractions. /l on day þ 11. On day þ 11, he developed grade-I acute GvHD of the skin, which was treated with methyl prednisolone 2 mg/ kg i.v. daily for 5 days followed by oral prednisolone, which was gradually tapered. He developed grade-IV acute GvHD of liver 9 months post transplant on cyclosporin taper. His liver function tests at that time were as follows: bilirubin 105 mmol/l, AST 70 IU/l and ALP 897 IU/l. He was treated with prednisolone 2 mg/kg orally once daily. His LFTs showed a brief improvement before deteriorating further, bilirubin 218 mmol/l, ALP 629 IU/l and AST 198 IU/l. At this stage, he was treated with Campath-1H 10 mg i.v. on days 1-5 (total dose 50 mg). He tolerated Campath without major side effects and his LFTs gradually improved over the next couple of weeks, normalising in 8 weeks post treatment. Similar to case 1, his bilirubin and AST normalised earlier prior to ALP (Figure 2 ). His ALP initially continued to rise and remained abnormal for about 2 years. At the last follow-up 5 years post transplant, his LFTs are normal. He continues to be in molecular remission and has had no major infective complications following Campath-1H treatment.
In the cases described above, Campath-1H resulted in significant improvement of grade-IV liver GvHD in one patient and normalisation of LFTs in the other patient without affecting their remission or chimerism status. Both these patients tolerated Campath-1H without any major side effects. To our knowledge, there are only a few case reports of use of Campath in acute GvHD. Varadi et al 9 used Campath-1G (10 mg daily for 4 days) successfully in a patient with grade-IV refractory acute liver GvHD following BMT for Ph þ CML. Carella et al used Campath-1H in three patients (two CML and one low grade NHL) with steroid refractory acute GvHD (mainly liver and GI) following allogeneic bone marrow transplant. All the three patients showed dramatic response with resolution of both liver and GI GvHD within a few weeks. They used a total dose of 73 mg in one of their patients; however, no doses were mentioned in the other two patients. All the three patients however had CMV reactivation. 10 Our two patients had excellent responses to Campath-1H, but apart from shingles in one patient did not develop any other viral reactivation. We used lower doses of Campath-1H (50 mg) in both patients, which may account for the decreased infectious complications. Both patients are in remission with 100% donor chimerism.
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